Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
REGULATORY
Regional Governors Club Urges Early Conclusion on HPV Vaccines
A group of five governors from the Chugoku western Japan region is nudging the health ministry to draw a conclusion as soon as possible on whether to reinstate what it calls “active recommendation” for HPV vaccines under the national immunization…
To read the full story
Related Article
- MSD Says to Ensure HPV Vaccine Supply in Japan, 4 Million-Plus Syringes for FY2022
March 30, 2022
- MHLW Panel OKs Mix-and-Match HPV Vaccines in “Catch-Up” Program
January 31, 2022
- Japan Panel OKs HPV “Catch-Up” Shots for Females Born in FY1997-FY2005
December 24, 2021
- MSD Japan Hails Resumption of HPV Vaccine Recommendation
November 29, 2021
- Japan Panel Agrees to Give Free “Catch-Up” HPV Shots
November 16, 2021
- Plaintiffs, Lawyers Re-Stress Opposition to HPV Vaccine Recommendation
November 15, 2021
- Japan to Reinstate HPV Vaccine Recommendation after 8 Years in Limbo
November 15, 2021
- MHLW Health Service Chief Wants Prompt Debate on HPV Recommendation
October 20, 2021
- Plaintiffs, Lawyers Renew Opposition to Restart of HPV Vaccine Recommendation
October 13, 2021
- LDP League Hails Start of Panel Discussions on HPV Vaccine Recommendation
October 13, 2021
- No Factor to Impede Reinstatement of HPV Vaccine Recommendation: Panels
October 4, 2021
- MHLW Panel to Discuss HPV Vaccine Recommendation on Oct. 1
September 29, 2021
- Japan to Start Discussions in October on Reinstating HPV Vaccine Recommendation
September 21, 2021
- Council to Discuss Resuming Active Recommendation of HPV Vaccines: Health Minister
September 1, 2021
REGULATORY
- Japan to Set Up Fund to Spur Generic Shakeup; CEA, Market Expansion Re-Pricing on Agenda
December 26, 2024
- Gist of FY2025 Drug Price Revision
December 26, 2024
- Chuikyo OKs Outline of FY2025 Off-Year Drug Price Revision
December 26, 2024
- DPP’s Tamaki Rails Against Govt’s Price Revision Decision
December 26, 2024
- Japan Doles Out Orphan Tags for Nihon Servier’s Vorasidenib, 11 More APIs
December 26, 2024
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…